- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of June 3
The Center for Biosimilars® recaps the top stories for the week of June 3, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of June 3.
Number 5: Prestige BioPharma announced that the European Medicines Agency will review its application for a proposed trastuzumab biosimilar, HD201.
Number 4: During this week’s 2019 American Society of Clinical Oncology Annual Meeting (ASCO), researchers presented the final overall survival results from the phase 3 HERITAGE study of biosimilar trastuzumab, Ogivri.
Number 3: Also at ASCO, Samsung Bioepis presented long-awaited 3-year results for its biosimilar trastuzumab, Ontruzant.
Number 2: With patents on reference products that treat multiple sclerosis set to expire soon in Latin America, a panel of experts published a set of recommendations on biosimilars in the region.
Number 1: Ahead of the anticipated 2019 marketing of FDA-approved anticancer biosimilars in the United States, a pharmacy benefit manager is launching an oncology biosimilar program.
Finally, last week, our e-newsletter asked whether you think other states will follow Colorado’s lead in capping patients’ costs for insulin.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
